In vivo selection of novel biotherapeutics | Zendy

Giulia Ruozi | Zendy; Mauro Giacca | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vivo selection of novel biotherapeutics

Author(s) -

Giulia Ruozi,

Mauro Giacca

Publication year - 2015

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.5247

Subject(s) - in vivo , medicine , selection (genetic algorithm) , computational biology , cancer research , biology , computer science , genetics , machine learning

There is an impelling demand to develop novel therapeutics against degenerative disorders. Approximately 30% of people over 80 years of age develop a dementia and 1-3% of those over 65 years have Parkinson’s disease. Over 17 million patients suffer from heart failure, mostly as a consequence of lack of cardiac regeneration after ischemic cardiomyocyte death. After 75 years of age, 30% of individuals undergo age-related macular degeneration, a major cause of irreversible blindness, and 50% develop presbycusis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research